Ambegaonkar BM - Search Results

1

Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.

Cao X, Ejzykowicz F, Ramey DR, Sajjan S, Ambegaonkar BM, Mavros P, Tunceli K. Cao X, et al. Among authors: ambegaonkar bm. Clin Ther. 2015 Apr 1;37(4):804-15. doi: 10.1016/j.clinthera.2014.12.019. Epub 2015 Jan 24. Clin Ther. 2015. PMID: 25626487

2

Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.

Laires PA, Ejzykowicz F, Hsu TY, Ambegaonkar B, Davies G. Laires PA, et al. J Med Econ. 2015;18(8):565-72. doi: 10.3111/13696998.2015.1031794. Epub 2015 Apr 10. J Med Econ. 2015. PMID: 25788039 Free article.

3

Attainment of goal and normalized lipid levels with lipid-modifying therapy in Malaysia.

Hsu TY, Chirovsky D, Moy FM, Ambegaonkar BM. Hsu TY, et al. Among authors: ambegaonkar bm. Clin Ther. 2013 Apr;35(4):450-60. doi: 10.1016/j.clinthera.2013.02.004. Epub 2013 Mar 5. Clin Ther. 2013. PMID: 23481458

4

Time to initiation of oral antihyperglycemic and statin therapy in previously untreated patients with type 2 diabetes in the United States.

Sun P, Tunceli K, Zhang Q, Seck T, Iglay K, Davies MJ, Ambegaonkar B, Radican L. Sun P, et al. Curr Med Res Opin. 2013 Jul;29(7):801-6. doi: 10.1185/03007995.2013.800473. Epub 2013 May 10. Curr Med Res Opin. 2013. PMID: 23621515

5

Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.

Ambegaonkar BM, Bash LD, Chirovsky DR, Jameson K, Grant S, Nocea G, Pettersson B, Sazonov V. Ambegaonkar BM, et al. Eur J Intern Med. 2013 Oct;24(7):656-63. doi: 10.1016/j.ejim.2013.07.005. Epub 2013 Aug 13. Eur J Intern Med. 2013. PMID: 23953848

6

Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study.

Jameson K, Amber V, D'Oca K, Mills D, Giles A, Ambegaonkar B. Jameson K, et al. Int J Clin Pract. 2013 Dec;67(12):1228-37. doi: 10.1111/ijcp.12238. Epub 2013 Aug 14. Int J Clin Pract. 2013. PMID: 23944233 Free PMC article.

7

Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong.

Ambegaonkar B, Chirovsky D, Tse HF, Lau YK, Tomlinson B, Li SK, Yue CS, Wong TH, Choi MC, Tunggal P, Sazonov V. Ambegaonkar B, et al. Adv Ther. 2012 May;29(5):427-41. doi: 10.1007/s12325-012-0017-9. Epub 2012 May 3. Adv Ther. 2012. PMID: 22562782

8

Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.

Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM. Ambegaonkar BM, et al. Atherosclerosis. 2014 Dec;237(2):829-37. doi: 10.1016/j.atherosclerosis.2014.10.105. Epub 2014 Nov 4. Atherosclerosis. 2014. PMID: 25463129

9

Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.

Lorenzi M, Ambegaonkar B, Baxter CA, Jansen J, Zoratti MJ, Davies G. Lorenzi M, et al. Clin Res Cardiol. 2019 May;108(5):487-509. doi: 10.1007/s00392-018-1379-z. Epub 2018 Oct 9. Clin Res Cardiol. 2019. PMID: 30302558

10

Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.

Kamal-Bahl S, Watson DJ, Ambegaonkar BM. Kamal-Bahl S, et al. Among authors: ambegaonkar bm. Clin Ther. 2009 Jan;31(1):130-40. doi: 10.1016/j.clinthera.2009.01.011. Clin Ther. 2009. PMID: 19243714

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters